Apheresis removes whole blood in order to take out a component in the blood, such as plasma. In the therapeutic setting, apheresis is using to remove blood cells or pathogenic components in the plasma using an automated system. The therapeutic use of apheresis is continually expanding, particularly its use in atherosclerotic diseases. Many of the indications for therapeutic apheresis affect the blood and vascular system by improving blood flow by decreasing viscosity or treating microangiopathic hemolytic anemia or coagulopathies. The focus of this review is on the application of therapeutic apheresis, specifically lipoprotein apheresis (LA), and vascular diseases, particularly familial hypercholesterolemia (FH), lipoprotein (a) (LP(a)) hyperlipoproteinemia, and peripheral vascular disease (PVD).
APHERESIS
There are many different apheresis procedures, some of which remove blood components (plasma, red blood cells, white blood cells, or platelets) and other that remove components in the plasma (LA apheresis or immunoadsoption). The majority of the systems use centrifugation to separate out the blood components although some use filtration or adsorption or a combination. The amount of the pathogenic substance removed is logarithmical correlated to the volume processed such that the initial removal is more efficient than later: 1 blood volume processed removes 63%, 1.5 volumes 78%, and 2.0 volumes 86%. The removal of substances that remain in the vasculature is more efficient than those that are distributes through multiple compartments. For example, removal of fibrinogen or IgM which are almost all intravascular, parallels the numbers above. The re-accumulation of the substance in the vascular depends on re-equilibration between compartments as well as substance synthesis and breakdown. This in turn will determine the apheresis procedure frequency. and grade 1A-B indication. Notable exception is the use of therapeutic plasma exchange for patients who have too small blood volume to undergo LA, who may be treated with plasma exchange for FH.
Therapeutic apheresis is also applied to a number of cardiac or vascular diseases (Table 2) , as well as microthrombotic hemolytic anemias (e.g., thrombotic thrombocytopenic purpura), thrombotic diseases (e.g., heparin-induced thrombocytopenia and thrombosis), autoimmune disease affecting the kidney vasculature (e.g., ANCA-associated rapidly progressive glomerulonephritis), diseases resulting in hyperviscosity (e.g., Waldenstrom's macroglobinemia, hyperleukocytosis), hypertriglyceridemic pancreatitis, or hemglobinopathies which affect the vasculature (e.g., sickle cell disease). 1
Lipoprotein apheresis
LA refers to the selective removal of atherogenic apo-B containing lipoproteins [low-density lipoprotein (LDL), very low-density lipoprotein (vLDL), Lp(a)] from plasma. 3 Importantly, LA has minimal effect on atheroprotective HDL blood levels. Indications for use of LA vary from country to country but include FH (homozygous and heterozygous forms), medication resistant, symptomatic hypercholesterolemia, hyper Lp(a), PVD. LA may also be used in a subset of patients with Focal Segmental Glomerular Nephritis, as well as a variety of other less common disorders. 1, 3, 4 There are at least 6 methods for performing LA. These include:
• Dextran sulfate columns (DSA), which use electrostatic charge for selective removal of apo-B containing lipoproteins from plasma, • Heparin extracorporeal LDL precipitation (HELP), which selectively precipitates atherogenic lipoproteins from acidified plasma, • Immunoadsorption columns which removes lipoproteins with anti-apo-B antibodies, • Double membrane filtration which removes large molecular weight proteins (including LDL) from plasma, • Direct adsorption of lipoproteins which uses polyacrylatecoated polyacrlyaminde beads to remove apo-B containing lipoproteins from whole blood, and • Dextran sulfate cellulose columns which also remove lipoproteins from whole blood.
Of these, only DSA and HELP are approved by the FDA for use in the United States. Overall, these different systems have similar potency in removing atherogenic lipoproteins from Abbreviations: ECP, extracorporeal photopheresis; EPGA, eosinophilic granulomatosis with polyangiitis; HBV-PAN, hepatitis B virus-associated polyarteritis nodosa; IA, immunoadsorption; NYHA, New York Heart Association; PAN, polyarteritis nodosa; TA, therapeutic apheresis; TPE, therapeutic plasma exchange. the circulation. Interestingly, a variety of other plasma proteins may be removed by LA including C-reactive protein (CRP), E-selectin, pentraxin 3 (PTX3), galectin-3 (Gal-3), and tumor necrosis factor α (TNFα), although the extent of removal of these other proteins varies among removal technologies. 5 Removal of these other proteins may play a role in the beneficial effects of LA. In one study, PTX3, which is a component of the humoral immunity produced following activation of the vessel wall, is associated with atherosclerotic disease, and individuals with FH have higher levels, was decreased with LA (20% with each HELP LA procedure) as well as fibrinogen levels (65%) and CRP (55%) in FH patients. 5 In another study, Gal-3, which is elevated in various systemic inflammatory disorders and predicts allcause mortality, was reduced by about 20% using HELP and DSA LA in FH patients. 6 Lastly, a study showed in FH patients using HELP, DS3 (DSA: 3,000 ml processed) or DSF (DSA: 4,200 ml processed) decreased levels of E-Selectin (about 20% on average), CRP (about 45% with HELP, 65% with DS3, and 75% with DSF on average), TNFα (about increased 10% with HELP, decrease by 15% with DS3 or DSF on average), and IL-6 (no change with HELP, increase by about 500% with DS3 and 700% with DSF). 7 Thus, LA may remove other mediators of atherosclerosis.
For most indications, LA treatments are performed weekly or biweekly due to the removal and rebound kinetics of atheogenic lipoproteins. Each treatment typically treats 1.5-2 plasma volumes. LA treatment results in an acute decrease of apo-B containing lipoproteins by 50-80% of pretreatment levels, while HDL levels typically decrease by less than 10%. Following the acute drop in LDL after a treatment, the level rapidly rises in a curvilinear manner with an eventual plateau at baseline in the absence of additional apheresis treatment. 8, 9 Thus, after a single procedure, the interval to return to baseline is approximately 14 days in FH patients. When performed biweekly, time-averaged concentration of LDL cholesterol can be calculated using the following formula 8 : time-averaged concentration = C post + 0.73 * (C pre − C post ), where C pre is the LDL cholesterol just before treatment and C post is the LDL cholesterol immediately after treatment. The concept of time-averaged concentration is important to discuss with patients and can be thought of as a "medication equivalent" effect.
LA is generally well tolerated. A retrospective analysis of approximately 11,000 apheresis procedures over a 20-year period using DFPP, immunoadsorption, HELP, DSA, and direct adsorption of lipoproteins reported similar rates of side effects across all platforms. 10 The overall incidence of adverse events was 5.5% with the incidence of serious adverse events, all allergic reactions, being 0.06%. The most common side effects were hypotension (0.67%), hypertension (0.63%), dizziness (1.97%), pain (0.82%), and vomiting (0.25%). These are typically transient and self-limited effects but may also be easily managed pharmacologically. In addition, some patients complain of general malaise, sometimes lasting a day or more after each treatment.
Concomitant treatment with an angiotensin-converting enzyme inhibitor can precipitate hypotensive reactions during apheresis using DSA and polyacrylate-based systems. This is due to activation the kinin-kallikrein system by the negatively charged resins. This results in the production of bradykinin. As angiotensin-converting enzyme inhibitors inhibit the breakdown of bradykinin, levels bradykinin build up and can result in hypotension, flushing, dyspnea, and bradycardia after even a few milliliters of blood are returned. This reaction is easily avoided by use of an alternative blood pressure medication (e.g., angiotensin receptor blocker), holding of the angiotensin-converting enzyme inhibitor medication 48-72 hours prior to apheresis treatment, or use of another apheresis system (e.g., HELP) if available.
APPLICATIONS TO ATHEROSCLEROTIC DISEASES

Familial hypercholesterolemia
FH is a genetic disorder that is caused by mutations in the LDL receptor. The LDL receptor is essential for clearance of the apolioprotein B containing lipoproteins: LDL, vLDL, and LP(a). 11 FH is characterized by severe hypercholesterolemia and premature coronary artery disease. 12 FH is heterogeneous with more than 100 mutations identified. 13 Patients that are homozygous for FH mutations have markedly elevated LDL cholesterol levels (800-1000 mg/dl) compared to heterozygous patients with only a single genetic mutation (300-500 mg/dl). 14 Although homozygous FH is rare (~1:1,000,000), the incidence of heterozygous FH is not uncommon (~1:500-1:1,000) and both groups are at an increased risk for cardiovascular disease.
Efficacy of LA for FH was initially demonstrated in a retrospective observational study of 130 patients with FH (homozygous and heterozygous). 12 Forty-three of these subjects had received LA with an average interval of 2 week. These patients had higher initial LDL levels as well as more comorbidities compared to those that received standard of care alone. There was a 72% reduction in the primary composite endpoint (nonfatal myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass graft surgery, coronary heart disease, and death) along with lower LDL levels and improved LDL:HDL ratios. Other studies have found similar reduction in cardiovascular disease endpoints. 15, 16 Importantly, a randomized study of 18 patients with heterozygous FH (the LACMART study) demonstrated regression of atherosclerotic lesions is coronary arteries as assessed by a decrease in plaque area and an increase in luminal area after 1 year of biweekly LA treatments. 17
LP(a) hyperlipoproteinemia
Lp(a) is a lipopriotein comprised of an apo(a) protein covalently linked to LDL. Apo(a) is variable in size and structurally related to interaction (Kringle) domains contained in clotting factors such as plasminogen. 18 Lp(a) levels are not normally distributed in the population, and those with elevated levels (variably defined as levels above 30-50 mg/dl) are at increased risk of cardiovascular and cerebrovascular events. 19 Several studies have systematically examined LA in patients with Lp(a) hyperlipidemia. [20] [21] [22] [23] One study, the Pro(a)LiFe study, 22 prospectively followed 170 consecutive subjects with progressive cardiovascular disease on maximal lifestyle and medical therapies. Subjects were treated with LA on a weekly basis using a variety of LA technologies. Major adverse coronary events and all cardiovascular events (with consist of major adverse coronary events and cerebrovascular events) were followed for 2 years. Compared with the 2 years preceding LA treatment, major adverse coronary events and all cardiovascular events decreased 78% and 75%, respectively, over the first 2 years of treatment. This result is even more dramatic when put in the context of a progressive disease which manifested as an increased incidence of major adverse coronary events (78%) and all cardiovascular events (56%) in the years prior to LA treatment in this population.
Another study examined LA in 20 patients with refractory angina and elevated Lp(a) levels. 23 In this single-blinded crossover study, subjects were treated weekly with LA or sham for 3 months. After a 1-month wash out period, they were crossed over to the other group. The primary endpoint of myocardial perfusion increased by 63% with LA compared to sham treatment. There was also a decrease in carotid atherosclerotic burden with LA compared to sham. These data support the use of LA in patients with acute cardiac syndromes in addition to prevention of new events in patients with chronic disease.
Peripheral vascular disease
PVD affects about 5% of the US population resulting in insufficient blood flow mostly to the legs as a result of atherosclerosis. In Japan, LA use for PVD has been routine for individuals with severe pain when walking relatively short distances, 1, 24 and is covered by government insurance in advanced and refractory PVD patients. 25 It has been shown that even a single LA treatment can improve blood flow in the forearm in an endothelial dependent manner 26 and that the improved blood flow is largely due to increased blood flow in surface capillaries with a smaller contribution by deeper arterioles. 27 A single randomized controlled trial in patients with FH and coronary atherosclerosis received simvastatin with or without biweekly LA for PVD demonstrated decreased number of patients with hemodynamically significant stenosis in the aortotibial tract and mean intima-media thickness with LA. 28 Other studies have shown clinical improvement and those with improvement have long-term reduction in levels of oxidized LDL, fibrinogen, and activated endothelial nitric oxide synthase. 24 
APHERESIS IN DEVELOPMENT
Fibrinogen absorption
Apheresis systems have been developed for fibrinogen absorption. 29, 30 This system uses a pentapeptide coupled to solid matrix to bind fibrinogen. The processing of 1,655 ml on average resulted in 64% decrease in fibrinogen level on average with significantly decreasing whole blood and plasma viscosity but not hemoglobin or the majority of clotting factors. Patients with foot ulcers where treated days 1, 2, 4, 6, 8, 10, 13, 16, 19, 22, 25 , and 28 with a goal to lower fibrinogen to 60-80 mg/dl with some patients have complete or accelerated wound healing. 29 This technology was also used to treat 10 patients with PVD who underwent a single treatment resulting in a 50% decrease in fibrinogen level and improvements in the walking distance test but not the ankle brachial index or Doppler tests. 31 Notably, plasma exchange on average removes 68-76% of fibrinogen per procedure and HELP removes 58-65% of fibrinogen. 32 This technology does not appear to be further developed or currently in use.
C-reactive protein
CRP is an acute-phase protein that binds to damaged tissue and results in complement activation. 33 CRP is a marker of cardiac risk and prognostic marker of outcome. In a porcine acute myocardial infarction model, 10 pigs received CRP depletion through selective apheresis with 5 controls. CRP-apheresis processed 2 blood volumes performed twice after infarction. CRP-apheresis treatment resulted in a mean reduction of CRP levels up to 48.3%, the area of infarction was significantly reduced (30% vs. 19%, P = 0.003), and improved left ventricular ejection fraction at 14 days (57.6% vs. 46.4%; P = 0.007). 33 Notably, LA also removes CRP, depending on the device and volume processed, 45-75% is removed on average per procedure. 5, 7 Additionally, there is debate if CRP plays a role in the pathogenesis or is only a marker of risk and prognosis. 34 
CONCLUSION
LA is successfully used in decreasing atherosclerotic events in patients with FH, Lp(a) hyperlipoproteinemia, and PVD. With the advent of new medications, especially PCSK9 inhibitors, LA role maybe reduced. 24 LA does more than remove LDL and lipoproteins but also decreases inflammatory markers and improves blood flow (through fibrinogen removal).
